SESN1: A Potential Drug Target Or Biomarker for Cancer (G27244)

Target Name: SESN1

NCBI ID: G27244

SESN1

SESN1: A Potential Drug Target Or Biomarker for Cancer

SESN1 (p53 activated gene 26) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. SESN1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells in the body. It is a key regulator of the p53 gene, which is a well-known tumor suppressor gene that plays a critical role in preventing the growth and proliferation of cancer cells.

SESN1 is composed of 21 amino acid residues and has a calculated molecular weight of 13.8 kDa. It is predominantly expressed in the cytoplasm of cultured cells and is also expressed in the nucleus of these cells. SESN1 is a strong RNA binding protein, and it has been shown to interact with various RNA molecules, including microRNAs and protein coding genes.

SESN1 has been shown to play a role in various cellular processes, including cell growth, apoptosis (programmed cell death), and DNA replication. It is well-known that p53 is a critical regulator of apoptosis, and that changes in p53 function have been implicated in the development and progression of many diseases, including cancer. Therefore, SESN1 has been a focus of interest for researchers because it is thought to be involved in the regulation of apoptosis and may be a potential drug target or biomarker.

SESN1 has been shown to interact with several proteins, including p53, p21 (a negative regulator of p53), and p16 (a tumor suppressor gene). It is also known to be regulated by various factors, including doublecortin, a microRNA that has been shown to interact with SESN1 and enhance its expression.

SESN1 has been shown to be involved in the regulation of cellular processes that are important for cancer development, including cell proliferation, apoptosis, and angiogenesis (the formation of new blood vessels). It is well-known that increased cell proliferation and apoptosis are key features of cancer development, and that inhibiting these processes may be an effective way to treat cancer. Therefore, SESN1 has been a potential drug target or biomarker for cancer.

SESN1 has also been shown to be involved in the regulation of DNA replication, which is a critical process for the development of cancer. It is well-known that changes in DNA replication have been implicated in the development of many diseases, including cancer. Therefore, SESN1 has been a potential drug target or biomarker for cancer because it may be involved in the regulation of DNA replication and the development of cancer.

In conclusion, SESN1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells in the body. It is a key regulator of the p53 gene and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and DNA replication. SESN1 has been shown to interact with several proteins, including p53, p21, and p16, and has been regulated by various factors, including doublecortin. SESN1 is thought to be involved in the regulation of apoptosis, cell proliferation, and DNA replication, which are key processes in the development and progression of cancer. Therefore, SESN1 is a potential drug target or biomarker for cancer. Further research is needed to fully understand the role of SESN1 in cancer development and treatment.

Protein Name: Sestrin 1

Functions: Functions as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway through the GATOR complex. In absence of leucine, binds the GATOR subcomplex GATOR2 and prevents TORC1 signaling. Binding of leucine to SESN2 disrupts its interaction with GATOR2 thereby activating the TORC1 signaling pathway (PubMed:25263562, PubMed:26449471). This stress-inducible metabolic regulator may also play a role in protection against oxidative and genotoxic stresses (By similarity). May positively regulate the transcription by NFE2L2 of genes involved in the response to oxidative stress by facilitating the SQSTM1-mediated autophagic degradation of KEAP1 (PubMed:23274085). Moreover, may prevent the accumulation of reactive oxygen species (ROS) through the alkylhydroperoxide reductase activity born by the N-terminal domain of the protein (By similarity). Was originally reported to contribute to oxidative stress resistance by reducing PRDX1 (PubMed:15105503). However, this could not be confirmed (By similarity)

The "SESN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SESN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets